Age and DMT Exposure May Predict Conversion From Clinically Isolated Syndrome to MSSeptember 24, 2014Multiple Sclerosis
Alemtuzumab’s Benefits May Be Sustained for Three Years in Patients With MSAugust 28, 2014Multiple Sclerosis
Clinical and Subclinical Factors Strongly Influence MS Treatment DecisionsAugust 28, 2014Multiple Sclerosis
Ofatumumab Reduces New Gadolinium-Enhancing Lesions With Partial B Cell DepletionJune 26, 2014Multiple Sclerosis
